In a recent interesting study, the in-vitro effect of the BCL2 inhibitor Venetoclax (ABT-199) was investigated on survival of the malignant cells isolated from the peripheral blood of CTCL patients [7]. Here, BCL2 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.